TB-500 is the common research name for a synthetic peptide fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in virtually all human and animal cells. It is one of the most abundant intracellular proteins in the body and plays central roles in cell migration, wound healing, and actin polymerization regulation. This is a research overview of what the published literature shows. This overview specifically addresses tb-500 (thymosin beta-4), and related research is indexed on PubMed.
What Is Thymosin Beta-4?
Thymosin Beta-4 was first isolated from thymic tissue in 1966 by Allan Goldstein at the Albert Einstein College of Medicine. It was initially investigated for immune system roles but subsequent research revealed its primary function involves actin sequestration — Tβ4 binds to G-actin monomers and regulates the equilibrium between polymerized F-actin and G-actin, which is fundamental to cell motility and wound repair.
TB-500 specifically refers to a fragment corresponding roughly to amino acids 17-23 of the Tβ4 sequence (Lys-Thr-Thr-Thr-Lys-Leu-Thr), the region believed responsible for much of its biological activity. Some research distinguishes between full-length Tβ4 and this fragment; the terms are often used interchangeably in the research compound community.
Published Research Areas
Wound Healing and Tissue Repair
This is the most-studied area with the most human data. A series of clinical trials conducted by RegeneRx Biopharmaceuticals (which holds Tβ4 patents) investigated topical Thymosin Beta-4 for corneal wound healing and pressure ulcers:
- Phase 2 trials of topical Tβ4 for corneal epithelial abrasion showed significant improvement in healing rates vs placebo
- Phase 2 trials for pressure ulcers showed reduced wound area at 12 weeks
- Topical formulation (RGN-259) received FDA orphan drug designation for neurotrophic keratopathy
These are the strongest human data points for any Thymosin Beta-4 formulation — though topical/local delivery differs significantly from systemic administration.
Cardiac Repair
Multiple rodent studies (including work from the NIH-funded labs of Deepak Srivastava at UCSF) demonstrated that Tβ4 pre-treatment before induced cardiac ischemia reduced infarct size and promoted cardiomyocyte survival. A 2004 Nature paper showed Tβ4 activated epicardial progenitor cells and stimulated coronary vasculogenesis in adult mice. This generated significant pharmaceutical interest.
Musculoskeletal
Rodent models of tendon, muscle, and ligament injury consistently show accelerated tissue repair with Tβ4 administration. The proposed mechanism involves enhanced myoblast and fibroblast migration to injury sites. Human data is absent.
Anti-inflammatory and CNS
Rodent studies show Tβ4 reduces pro-inflammatory cytokines (TNF-α, IL-1β) and promotes remyelination in spinal cord injury models. CNS research is at early preclinical stages.
Evidence Summary
- Wound healing (topical): Human Phase 2 data exists — strongest evidence base
- Cardiac: Robust rodent data, no human trials for systemic use
- Musculoskeletal: Rodent data only
- Systemic injectable use: No published human RCT data
The “Fragment” Naming Confusion
A persistent point of confusion in the research-compound market is that “TB-500” is often marketed as though it were a specific, defined fragment of Thymosin Beta-4 — but the actual TB-500 designation historically referred to a 43-amino-acid sequence essentially identical to full-length Tβ4 itself, not to the smaller “Ac-SDKP” or “LKKTET” fragments that some literature discusses separately for their independent actin-regulatory and cell-migration effects. Products sold under the TB-500 name in the RUO marketplace have been found in independent testing to vary between full-length Tβ4 and shorter synthesized fragments depending on the manufacturer, meaning “TB-500” functions more as a loosely applied brand name than a single defined chemical entity — a distinction worth understanding before comparing studies or COA data across different vendor products.
RegeneRx’s Clinical Development Program
The most clinically advanced Tβ4-based development work has come from RegeneRx Biopharmaceuticals, which has pursued Tβ4-derived drug candidates through FDA-regulated trial pathways for specific indications — including a topical formulation studied for dermal wound healing and a separate ophthalmic formulation studied for corneal and dry-eye conditions. This represents a materially different development path than the injectable RUO products sold under the TB-500 name: RegeneRx’s programs involve purpose-built formulations, defined delivery routes (topical/ophthalmic, not systemic injection), and FDA-overseen trial protocols, none of which apply to peptides purchased as research chemicals. The existence of a legitimate pharmaceutical development program for Tβ4 derivatives is sometimes cited as validation for injectable RUO use, which is a mischaracterization of what that clinical work actually studied.
The Actin-Sequestering Mechanism in Plain Terms
Thymosin Beta-4’s core cellular function is binding to G-actin (the monomeric form of the actin protein) and regulating its polymerization into F-actin filaments — the structural scaffolding cells use to change shape, migrate, and form the leading edge during movement. This actin-regulatory role is why Tβ4 shows up so consistently across wound-healing, cell-migration, and tissue-remodeling research: nearly every process involving cells moving into a wound site or reorganizing tissue structure depends on actin dynamics. It’s a genuinely fundamental cell-biology mechanism, but “regulates a fundamental cellular process” is a different claim than “safely and predictably improves outcomes when injected systemically in humans” — the gap between mechanistic plausibility and established injectable safety/efficacy data remains wide for this compound.
Frequently Asked Questions
Is TB-500 the same thing as Thymosin Beta-4?
Largely yes — “TB-500” as commonly sold is essentially identical or very similar to full-length Tβ4, despite being marketed with fragment-like naming. Independent testing has found variability across vendors in what’s actually in TB-500-labeled products.
Does RegeneRx’s FDA trial work validate injectable TB-500 use?
No. RegeneRx’s Tβ4-derived clinical programs studied topical and ophthalmic formulations for specific conditions under FDA oversight — a different product, delivery route, and regulatory pathway than injectable research-chemical TB-500, and this distinction is frequently lost in secondhand summaries.
Why is Tβ4’s actin-binding function considered important?
Actin polymerization underlies cell migration and shape change, which are central to wound healing and tissue remodeling — Tβ4’s role in this process is well established at the cell-biology level, even though this doesn’t by itself establish safety or efficacy for systemic human use.
Educational content only. TB-500 is a research compound with no approved human injectable application. Not medical advice.
